
STATUS UPDATE:

- (A) APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY**
 - (B) ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN KAO KUN**
 - (C) UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA**
 - (D) UPDATES TO SHAREHOLDERS ON OTHER CLAIM(S) AGAINST OUE LIPPO HEALTHCARE LIMITED**
-

1. INTRODUCTION

1.1. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in:

- (a) the announcements of OUE Lippo Healthcare Limited (the "**Company**") between 3 May 2016 to 30 March 2020, in relation to, *inter alia*, the appointment of receivers over certain subsidiaries of the Company¹;
- (b) the announcements of the Company between 13 December 2017 to 22 April 2020 in relation to the arbitration and enforcement proceedings against David Lin Kao Kun ("**David Lin**")²; and
- (c) the announcements of the Company between 22 February 2017 to 30 December 2019 in relation to on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) ("**Weixin**")³.

¹ Please refer to the Company's announcements dated 3 May 2016, 6 May 2016, 8 July 2016, 8 August 2016, 15 August 2016, 16 September 2016, 13 October 2016, 21 October 2016, 14 November 2016, 24 November 2016, 15 December 2016, 13 January 2017, 11 March 2017, 29 April 2017, 17 May 2017, 16 June 2017, 29 June 2017, 13 July 2017, 22 August 2017, 28 September 2017, 25 October 2017, 22 November 2017, 28 December 2017, 24 January 2018, 28 February 2018, 27 March 2018, 30 April 2018, 28 May 2018, 26 June 2018, 2 July 2018, 26 July 2018, 27 August 2018, 27 September 2018, 29 October 2018, 30 November 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 15 September 2019, 30 September 2019, 30 October 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, and 30 March 2020.

² Please refer to the Company's announcements dated 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019, 29 April 2019, 31 May 2019, 26 June 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 30 October 2019, 3 November 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020 and 22 April 2020.

³ Please refer to the Company's announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 14 October 2019, 30 October 2019, 25 November 2019, 29 November 2019, 12 December 2019 and 30 December 2019, 31 January 2020, 28 February 2020 and 30 March 2020.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

2. APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY

2.1. Aathar's Voluntary Arrangement

As announced previously on 28 February 2020, Aathar obtained the Official Assignee's permission to proceed with his Appeal against the decision to revoke his third voluntary arrangement (the "**Appeal**"). The Appeal was part-heard on 14 January 2020 and 21 February 2020.

As announced previously on 30 March 2020, the further hearing for this matter had been fixed on 8-9 April 2020. These hearing dates have been vacated and the further hearing for this matter has yet to be fixed.

There are no material updates on the other proceedings with the Crest Entities.

3. ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN

3.1 Enforcement proceedings in Taiwan

As announced previously on 31 January 2020, the Company has obtained a final order from Taiwan High Court recognising the Arbitration Award in Taiwan. The Company has proceeded with enforcement proceedings before the Taipei District Court on 31 March 2020 against David Lin's assets in Taiwan. The Taipei District Court granted the Company's application and commenced the final enforcement proceedings on 16 April 2020. The final enforcement proceedings are ongoing.

3.2 Enforcement Proceedings in Hong Kong

As announced previously on 30 December 2019, on 2 December 2019, the Hong Kong Court granted Garnishee Orders Absolute (final attachment) over the monies in David Lin's bank accounts with Chiyu Bank Corporation Limited and the Bank of China (Hong Kong) Limited.

As announced previously on 31 January 2020, on 22 January 2020, the Company filed two applications to vary the Mareva Injunction Order (the "**Variation Applications**"). In the Variation Applications, the Company applied for the Mareva Injunction Order to be varied so that the monies in David Lin's bank accounts with Chiyu Bank Corporation Limited and the Bank of China (Hong Kong) Limited may be paid to the Company.

On 5 March 2020, Chiyu Bank Corporation Limited and the Bank of China (Hong Kong) Limited transferred the monies in David Lin's bank accounts to the Company's Hong Kong counsel pursuant to the Garnishee Orders Absolute. The Company's Hong Kong counsel have since applied to withdraw the Variation Applications, pending confirmation from the Hong Kong Court.

4. VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA

There are no material updates for the various litigation proceedings in the People's Republic of China.

5. UPDATES TO SHAREHOLDERS ON OTHER CLAIM(S) AGAINST OUE LIPPO HEALTHCARE LIMITED

There are no material updates on the other claims against the Company.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
29 April 2020

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).